| Name | Role | Date | Shares | Price | Value |
|---|---|---|---|---|---|
| Stephen J. Hill | COO | 2026-08-10 | 89 | $14.34 | $1.28kSell |
| Lynn Seely | CEO;Pres | 2026-08-10 | 390 | $14.34 | $5.59kSell |
| Gary K. Lee | CSci | 2026-08-10 | 131 | $14.34 | $1.88kSell |
| Veronica Sanchez Bulis | Ctrl;VP | 2026-08-10 | 621 | $14.34 | $8.91kSell |
| Innovative Cellular Therapeutics Holdings Ltd | 10% Owner | 2026-07-17 | 10 | $13.70 | $137.00Sell |
| Cellular Therapeuti Innovative | 10% Owner | 2026-07-17 | 10 | $13.70 | $137.00Sell |
| Innovative Cellular Therapeutics Holdings Ltd | 10% Owner | 2026-07-16 | 10 | $13.73 | $137.30Sell |
| David Shook | Chief Medical Officer | 2026-06-10 | 1,977 | $12.64 | $24.99kSell |
| Lynn Seely | President and CEO | 2026-05-11 | 388 | $18.91 | $7.34kSell |
| Gary K. Lee | Chief Scientific Officer | 2026-05-11 | 130 | $18.92 | $2.46kSell |
| Name | Hold | Shares | Value | Type |
|---|---|---|---|---|
| Robert Nelsen | 222.89% | 54,619,074 | $761.94M | Insider |
| Arch Venture Partners IX LLC | 159.74% | 39,143,667 | $546.05M | Insider |
| Glaxosmithkline PLC | 123.46% | 30,253,189 | $422.03M | Insider |
| Richard Klausner | 23.02% | 5,641,764 | $78.70M | Insider |
| Hans Edgar Bishop | 19.12% | 4,685,614 | $65.36M | Insider |
| Cellular Therapeuti Innovative | 11.66% | 2,857,480 | $39.86M | Insider |
| Innovative Cellular Therapeutics Holdings Ltd | 11.66% | 2,857,480 | $39.86M | Insider |
| Cellular Therapeutics Holding Innovative | 11.32% | 2,774,980 | $38.71M | Insider |
| Arch Venture Fund XIII LP | 7.54% | 1,848,755 | $25.79M | Insider |
| Cathy Friedman | 1.03% | 253,188 | $3.53M | Insider |